Form 8-K - Current report:
SEC Accession No. 0001689375-25-000009
Filing Date
2025-02-27
Accepted
2025-02-27 07:02:09
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trda-20250227.htm   iXBRL 8-K 28635
2 EX-99.1 q4earningsrelease.htm EX-99.1 66678
6 GRAPHIC image_0.jpg GRAPHIC 30141
  Complete submission text file 0001689375-25-000009.txt   277396

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trda-20250227.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT trda-20250227_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT trda-20250227_pre.xml EX-101.PRE 13585
17 EXTRACTED XBRL INSTANCE DOCUMENT trda-20250227_htm.xml XML 2928
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

EIN.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40969 | Film No.: 25672933
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)